- idUS
- Listar por autor
Listar por autor "Cobo, Manuel"
Mostrando ítems 1-3 de 3
-
Artículo
Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis
Arriola, Edurne; González Cao, María; Domine, Manuel; De Castro, Javier; Cobo, Manuel; Bernabé-Caro, Reyes; Isla, Dolores (SPRINGER, 2022)Introduction The addition of immune checkpoint inhibitors (ICIs) to conventional chemotherapy (CT) as first-line treatment ...
-
Artículo
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
Provencio, Mariano; Cobo, Manuel; Rodríguez Abreu, Delvys; Calvo, Virginia; Carcereny, Enric; Cantero, Alexandra; Bernabé-Caro, Reyes; Torrente, Ana (BMC, 2022)Background: The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This ...
-
Artículo
PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis
Majem, Margarita; Cobo, Manuel; Isla, Dolores; Márquez Medina, Diego; Rodríguez Abreu, Delvys; Casal Rubio, Joaquín; Bernabé-Caro, Reyes; Paz-Ares Rodriguez, Luis (MDPI, 2021-03-26)Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selection of patients more likely to respond ...